Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant improvement in progression-free survival for patients with EGFR exon 20 insertion mutations. The companies plan to submit full results for presentation at an upcoming medical conference and pursue U.S. regulatory approval. Zipalertinib would compete with Johnson & Johnson's amivantamab (Rybrevant) i
How this was made
The 30-second read
Why it matters
Positive interim PFS data may accelerate FDA discussions and increase market enthusiasm for CGEM.
Market read
First report of pivotal trial data for a late‑stage oncology asset, likely to move CGEM and affect the NSCLC therapeutic sector.
What to watch
Regulatory timeline uncertainties and competition from established IV therapies may limit upside.
Background
The REZILIENT3 trial compares zipalertinib plus chemotherapy vs chemotherapy alone in EGFR exon 20 NSCLC patients.
Ticker impact
Cullinan Therapeutics reported positive interim Phase 3 data for zipalertinib in NSCLC, a first disclosure.
Potential upside of 15-25% over the next 2-3 months if data holds.
Phase 3 interim success is material for a biotech; market typically rewards such milestones.
Market effects
Strengthens the EGFR exon 20 NSCLC therapeutic segment, may pressure competitors like amivantamab.
Highlights Japan's Otsuka/Taiho oncology pipeline, could attract regional biotech investors.
Adds a potential oral alternative to the global NSCLC treatment landscape.
Counterpoint
If the full data fails to confirm interim benefit, the stock could sharply reverse.
Key entities
- CompanyCullinan Therapeutics
Nasdaq-listed biotech developing zipalertinib.
- CompanyTaiho Pharmaceutical
Japanese pharma subsidiary of Otsuka, partner in the trial.
